SAN JOSE, Calif. , June 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host an investor webcast presentation on June 26, 2025 at 2:00 PM EDT.
Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
SAN JOSE, Calif. , June 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its CEO, Dr. Amit Kumar, was interviewed by the New York Post to discuss Anixa's breast cancer vaccine, and the breast cancer vaccine was featured on Fox News' "Fox & Friends.
6 Jun 2025 Date | | - Cons. EPS | - EPS |
21 Mar 2025 Date | | - Cons. EPS | - EPS |
6 Sep 2024 Date | | - Cons. EPS | - EPS |
4 Jun 2024 Date | | - Cons. EPS | - EPS |
9 May 2024 Date | | - Cons. EPS | - EPS |
6 Jun 2025 Date | | - Cons. EPS | - EPS |
21 Mar 2025 Date | | - Cons. EPS | - EPS |
6 Sep 2024 Date | | - Cons. EPS | - EPS |
4 Jun 2024 Date | | - Cons. EPS | - EPS |
9 May 2024 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Dr. Amit Kumar Ph.D. CEO | NASDAQ (CM) Exchange | 03528H109 Cusip |
US Country | 5 Employees | - Last Dividend | 26 Jun 2015 Last Split | 1 Jan 1987 IPO Date |
Anixa Biosciences, Inc. is a pioneering biotechnology enterprise committed to the innovation of novel treatments and vaccines addressing the urgent needs within oncology and infectious diseases sectors. Since its inception in 1982 and formerly known as ITUS Corporation before rebranding in October 2018, Anixa has been at the forefront of developing groundbreaking therapies. Headquartered in San Jose, California, the company concentrates on leveraging advancements in science and technology to create solutions for diseases with significant unmet medical needs, particularly focusing on various forms of cancer.
This novel form of chimeric antigen receptor T-cell (CAR-T) technology is under development by Anixa Biosciences with a primary focus on treating ovarian cancer. By tailoring the body's own immune cells to better recognize and fight cancer, this therapy represents a promising advance in personalized medicine for ovarian cancer patients.
An innovative project undertaken by Anixa is the development of a vaccine aimed at combating triple negative breast cancer. This form of breast cancer is particularly challenging to treat due to the lack of hormone receptors, which are typically targeted in other breast cancer treatments. Anixa's vaccine seeks to stimulate the immune system to prevent or treat this aggressive type of cancer.
Focusing on prevention, Anixa is also working on a vaccine aimed at ovarian cancer, one of the most deadly forms of gynecological cancer. The goal of this vaccine is to train the immune system to recognize and eliminate cells that could potentially develop into cancer, thus offering a prophylactic solution to high-risk individuals.
Aside from vaccines and targeted cell therapies, Anixa Biosciences is also developing a range of immuno-therapy drugs designed to empower the immune system in fighting against cancer. These drugs work by various mechanisms to enhance the body's natural defense systems, showing promise in treating different types of cancer.